Summary
Monitoring SARS-CoV-2 spread and evolution through genome sequencing is essential in handling the COVID-19 pandemic. The availability of patient hospital records is crucial for linking the genomic sequence information to virus function during the course of infections. Here, we sequenced 892 SARS-CoV-2 genomes collected from patients in Saudi Arabia from March to August 2020. From the assembled sequences, we estimate the SARS-CoV-2 effective population size and infection rate and outline the epidemiological dynamics of import and transmission events during this period in Saudi Arabia. We show that two consecutive mutations (R203K/G204R) in the SARS-CoV-2 nucleocapsid (N) protein are associated with higher viral loads in COVID-19 patients. Our comparative biochemical analysis reveals that the mutant N protein displays enhanced viral RNA binding and differential interaction with key host proteins. We found hyper-phosphorylation of the adjacent serine site (S206) in the mutant N protein by mass-spectrometry analysis. Furthermore, analysis of the host cell transcriptome suggests that the mutant N protein results in dysregulated interferon response genes. We provide crucial information in linking the R203K/G204R mutations in the N protein as a major modulator of host-virus interactions and increased viral load and underline the potential of the nucleocapsid protein as a drug target during infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KAUST Rapid Research Response Team (R3T) by Vice President Research (VPR) office in KAUST. KAUST faculty baseline fund (BAS/1/1020-01-01) to AP. KACST Grants, Proposal number: 5-20-01-002-0008 MOH COVID-19 project grants number 341 MOH COVID-19 project grants number 754 The deputyship for Research and Innovation, Ministry of Education in Saudi Arabia, project number (436) to AMH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was conducted under the IRB approvals of the MOH (H-02-K-076-0420-285), KAUST (20IBEC14) and at the Dr. Suliman Al-Habib Medical group (HAP-01-R-082) in KSA.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Assembled virus genomes are available at GISAID (Table S1). Reads from RNA-Seq analysis of transfected HEK293T cells have been uploaded to European Nucleotide Archive (https://www.ebi.ac.uk/ena/) under the Study accession number PRJEB44716
